177Lu-octreotate, alone or with radiosensitising chemotherapy, is safe in neuroendocrine tumour patients previously treated with high-activity 111In-octreotide

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 10, 2010, Pages 1869-1875

  Hubble, Daniel ^a   Kong, Grace ^a   Michael, Michael ^a   Johnson, Val ^a   Ramdave, Shakher ^a   Hicks, Rodney John ^a  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

Author keywords

177Lu octreotate; Carcinoid; Neuroendocrine tumours; Radionuclide therapy; Toxicity

Indexed keywords

CAPECITABINE; CREATININE; FLUOROURACIL; OCTREOTATE LU 177; PENTETREOTIDE IN 111; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 177LU OCTREOTATE; 177LU-OCTREOTATE; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; INDIUM 111 OCTREOTIDE; INDIUM-111-OCTREOTIDE; OCTREOTIDE; ORGANOMETALLIC COMPOUND; PRODRUG; RADIOSENSITIZING AGENT; RECEPTOR;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD CELL COUNT; BLOOD TOXICITY; BONE MARROW DEPRESSION; BONE METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DEATH; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; LYMPHOCYTOPENIA; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; NEUROENDOCRINE TUMOR; NEUTROPENIA; OVERALL SURVIVAL; PATIENT SAFETY; RADIOSENSITIZING CHEMOTHERAPY; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TOXICITY; TREATMENT DURATION; BLOOD; BLOOD EXAMINATION; DRUG EFFECT; KIDNEY; METABOLISM; MIDDLE AGED; SURVIVAL; TIME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HEMATOLOGIC TESTS; HUMANS; KIDNEY; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; OCTREOTIDE; ORGANOMETALLIC COMPOUNDS; PRODRUGS; RADIATION-SENSITIZING AGENTS; RECEPTORS, PEPTIDE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TIME FACTORS; YOUNG ADULT;

EID: 79952112450     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-010-1483-4     Document Type: Article

References (20)

1. Klöppel G. Tumour biology and histopathology of neuroendocrine tumours. Best Pract Res Clin Endocrinol Metab 2007;21(1):15-31.
2. Öberg K. Chemotherapy and biotherapy in neuroendocrine tumors. Curr Opin Oncol 1993;5:110-20.
3. Eriksson B, Öberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol 1999;10(Suppl 2):S31-8.
4. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009;27:4656-63.
5. Anthony LB, Woltering EA, Espanan GD, Cronin MD, Maloney TJ, McCarthy KE. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002;32:123-32.
6. Valkema R, De Jong M, Bakker WH, Breeman WA, Kooij PP, Lugtenburg PJ, et al. Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience. Semin Nucl Med 2002;32:110-22.
7. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439-47.
8. Waldherr C, Pless M, Maecke HR, Schumacher T, Crazzolara A, Nitzsche EU, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002;43:610-6.
9. Valkema R, Pauwels S, Kvols L, Jamar F, Barone R, Bakker WH, et al. Long-term follow-up of a phase 1 study of peptide receptor radionuclide therapy (PRRT) with [90Y-DOTA0, Tyr3]octreotide in patients with somatostatin receptor positive tumours [abstract]. Eur J Nucl Med Mol Imaging 2003;30 Suppl 2:S232.
10. Kwekkeboom DJ, Bakker WH, Kooij PP, Konijnenberg MW, Srinivasan A, Erion JL, et al. [177Lu-DOTA0Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients. Eur J Nucl Med 2001;28:1319-25.
11. Kwekkeboom D, De Herder W, Kam B, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabelled somatostatin analog [177Lu-DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008;26(13):2124-30.
12. Kong G, Johnston V, Ramdave S, Lau E, Rischin D, Hicks RJ. High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm 2009;24(5):527-33.
13. Rolleman EJ, Valkema R, de Jong M, Kooij PP, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging 2003;30:9-15.
14. Behr TM, Goldenberg DM, Becker W. Reducing the renal uptake of radiolabeled antibody fragments and peptides for diagnosis and therapy: present status, future prospects and limitations. Eur J Nucl Med 1998;25:201-12.
15. Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005;46:1310-6.
16. Sierra ML, Agazzi A, Bodei L, Pacifici M, Aricò D, De Cicco C, et al. Lymphocytic toxicity in patients after peptide-receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE and 90Y-DOTATOC. Cancer Biother Radiopharm 2009;24(6):659-65.
17. Konijnenberg MWE, Bijster M, Krenning E, De Jong M. A stylized computational model of the rat for organ dosimetry in support of preclinical evaluations of peptide receptor radionuclide therapy with (90)Y, (111)In, or (177)Lu. J Nucl Med 2004;45:1260-9.
18. Flynn AA, Pedley RB, Green AJ, Dearling JL, El-Emir E, Boxer GM, et al. The nonuniformity of antibody distribution in the kidney and its influence on dosimetry. Radiat Res 2003;159:182-9.
19. Kwekkeboom D, Bakker W, Kam BLR, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somato-statin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417-22.
20. van Essen M, Krenning EP, Kam BL, de Herder WW, van Aken MO, Kwekkeboom DJ. Report on short-term side effects of treatments with 177Lu-octreotate in combination with capecitabine in seven patients with gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2008;35:743-8.